News Report | March 31, 2019
FDA Approves Zulresso, First Drug For Postpartum Depression
On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso, the first drug specifically for treatment of postpartum depression (PPD). Zulresso, or brexanolone, is an injection for intravenous use. Zulresso was evaluated by the FDA under priority review, and approval of Zulresso was granted to Sage Therapeutics, Inc. The commercial launch of Zulresso is expected by late June 2019.
Zulresso is administered as a continuous IV infusion over a total of 60 hours, or 2.5 days. The treatment must be administered by a health care professional in a certified health care facility. Clinical trials indicate . . .